Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALPN
- Price
- -
- Stock movement down
- -0.30 (-3.85%)
- Company name
- Alpine Immune Sciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 514.48M
- Ent value
- 522.41M
- Price/Sales
- 9.10
- Price/Book
- 1.55
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -24.56%
- 1 year return
- -28.02%
- 3 year return
- -8.31%
- 5 year return
- 11.14%
- 10 year return
- -
Last updated: 2024-12-16
DIVIDENDS
ALPN does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9.10 |
| Price to Book | 1.55 |
| EV to Sales | 9.24 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 68.60M |
| EPS (TTM) | -0.58 |
| FCF per share (TTM) | -1.26 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 56.52M |
| Gross profit (TTM) | 55.94M |
| Operating income (TTM) | -51.35M |
| Net income (TTM) | -36.84M |
| EPS (TTM) | -0.58 |
| EPS (1y forward) | -2.00 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 98.97% |
| Operating margin (TTM) | -90.86% |
| Profit margin (TTM) | -65.17% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 33.02M |
| Net receivables | 543.00K |
| Total current assets | 308.25M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 8.67M |
| Total assets | 373.65M |
| Accounts payable | 4.17M |
| Short/Current long term debt | 9.65M |
| Total current liabilities | 32.24M |
| Total liabilities | 40.94M |
| Shareholder's equity | 332.70M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -80.55M |
| Capital expenditures (TTM) | 413.00K |
| Free cash flow (TTM) | -80.96M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -11.07% |
| Return on Assets | -9.86% |
| Return on Invested Capital | -11.04% |
| Cash Return on Invested Capital | -24.27% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ALPN | S&P500 | |
| Current price drop from All-time high | -90.70% | -2.81% |
| Highest price drop | -97.33% | -56.47% |
| Date of highest drop | 17 Mar 2020 | 9 Mar 2009 |
| Avg drop from high | -82.84% | -10.99% |
| Avg time to new high | 175 days | 12 days |
| Max time to new high | 2228 days | 1805 days |
COMPANY DETAILS
Marketcap
514.48M
Marketcap category
Small-cap
Description
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.
Employees
142
Investor relations
-
SEC filings
CEO
Mitchell H. Gold
Country
USA
City
Seattle
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner